MENU

ATXS Stock Astria Therapeutics (ATXS, $9.43) Stochastic Oscillator left the oversold zone on May 16, 2024

A.I.dvisor
at Tickeron.com
05/17/24
Loading...
ATXS - Astria Therapeutics
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $9.43
Daily change: +$0.16 (+1.73%)
Daily volume: 394.8K
Capitalization: $517.8M
Industry: Biotechnology
This is a signal that ATXS's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 63 similar cases where ATXS's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

ATXS sees MACD Histogram crosses below signal line

ATXS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ATXS as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ATXS moved below its 50-day moving average on November 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ATXS crossed bearishly below the 50-day moving average on November 13, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

ATXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 225 cases where ATXS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.383) is normal, around the industry mean (14.905). P/E Ratio (0.000) is within average values for comparable stocks, (98.894). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.944). ATXS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (217.940).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
ATXS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com